The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

GSK’s MenABCWY vaccine is an injectable suspension intended for intramuscular use. It comes with a vial of lyophilised ...

GSK’s 5-in-1 meningococcal vaccine, Penmenvy receives US FDA approval to help protect against MenABCWY: London, UK Monday, February 17, 2025, 10:00 Hrs [IST] GSK plc announced t ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

The safety data demonstrated that the vaccine has a safety profile consistent with GSK’s licensed meningococcal ... in the U.S., positioning the company well to lead in the U.S. market as ...

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

GSK has shifted towards a global marketing ... While the new CEO has made some high-profile changes to the company’s management team, there have been some changes to the way the company ...

In the midst of that, Hanon left GSK in April after 20 years at the company, including seven as ... Meanwhile it is also bringing some other high-profile new vaccines through late-stage ...